Skip to main content
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

2,348

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

2,348 results for “type 1 diabetes”

Learn how ShareScore rates datasets ↗
dryad36/100

Data from: A genome-wide functional genomics approach uncovers genetic determinants of immune phenotypes in type 1 diabetes

Open the record for dataset details and reuse information.

publicJun 2022View details →
dryad36/100

Small things matter: Lack of extra-islet β-cells in Type 1 diabetes

Open the record for dataset details and reuse information.

publicOct 2025View details →
dryad36/100

Risk factors for cardiovascular disease (CVD) in adults with type 1 diabetes: findings from prospective real-life T1D exchange registry

Open the record for dataset details and reuse information.

publicMar 2020View details →
dryad32/100

Impact of COVID-19 lockdown on glycemic control in adults with type 1 diabetes mellitus: information and standardized questions regarding follow-up during lockdown

<p>Aim. To examine the impact of the lockdown caused by COVID-19 pandemic on both the glycemic control and the daily habits of a group of patients with type 1 diabetes mellitus (T1DM) using flash continuous glucose monitoring devices (Flash CGM). </p> <p>Methods. Retrospective analysis based on all the information gathered in virtual consultations from a cohort of 50 adult patients with T1DM with follow-up at our site. We compared their CGM metrics during lockdown with their own previous data before the pandemic occurred, as well as the potential psychological and therapeutic changes.</p> <p>Results. We observed a reduction of the average glucose: 160.26 ± 22.55 mg/dl vs. 150 ± 20.96 mg/dl, p=0.0009, estimated HbA1c: 7.21 ± 0.78% vs. 6.83 ± 0.71%, p=000.5, glucose management indicator (GMI) 7.15 ± 0.57 % vs. 6.88 ± 0.49 %, p=0.0003, and glycemic variability (CV): 40.74 ± 6.66 vs. 36.43 ± 6.09 p&lt;0.0001. Time in range showed an improvement: 57.46 ± 11.85% vs a 65.76 ± 12.09%, p&lt;0.0001, without an increase in percentage of time in hypoglycaemia.</p> <p>Conclusions: COVID-19 lockdown was associated with an improvement in glycemic control in patients with T1DM using CGM.</p>

opencc-zeroSep 2020View details →
zenodo32/100

Self-care activities in pediatric patients with type 1 diabetes mellitus

Open the record for dataset details and reuse information.

opencc-by-4.0Dec 2023View details →
zenodo32/100

Data for publication ''Interactive nutrition education is more effective in terms of improved levels of glycated hemoglobin in adolescent patients with poorly controlled type 1 diabetes – a randomized study''

<p>Data present changes in the most important clinical parameters after 3 and 6 months from the applied educational intervention in the group of children and adolescents with type 1 diabetes.</p>

opencc-by-4.0Oct 2019View details →
zenodo32/100

Data for publication on the impact of two different nutrition education methods on the quality of life of children and adolescents with type 1 diabetes (randomized study)

<p>Data present changes in the quality of life 6 months after the educational intervention applied in the group of children and adolescents with type 1 diabetes.</p>

opencc-by-4.0Nov 2019View details →
zenodo32/100

Peptide Pool Instability of Precancerous Lesion in Rats with Model of Chronic Pancreatitis and/or Without Type 1 Diabetes Mellitus

<p><span><strong>Supplementary table 1. </strong>Data of Shapiro-Wilk (W) normality test and Homogeneity of Variance Test (Levene's F Test).</span></p> <p>&nbsp;</p> <p><span><strong>Supplementary table 2. </strong>Kruskal-Wallis as the overall test (H-values) and posthoc Dunn's test with Bonferroni correction. The corrected &alpha; using the Bonferroni correction method is 0.017</span></p>

opencc-by-4.0Sep 2024View details →
zenodo32/100

Electrogenetic cellular insulin release for real-time glycemic control in type 1 diabetic mice

<p>Data underlying the figures in the publication &ldquo;Electrogenetic cellular insulin release for real-time glycemic control in type 1 diabetic mice&rdquo;, published in <em>Science</em>, <strong>2020</strong>, 368, 993-1001. <a href="https://science.sciencemag.org/content/368/6494/993">https://science.sciencemag.org/content/368/6494/993</a></p> <p>Table of contents:</p> <p><strong>1. Electrogenetics source data file</strong>; File openable with Graphpad Prism containing the source data for the main <em>Figures: 1-4 </em>(Transgene expression by SEAP measurement), <em>5b, 6a, 6f</em> (Insulin by ELISA), <em>5c, 6b, 6e </em>(NanoLuc luciferase), 7c (NanoLuc luciferase in vivo) and <em>7a, 7d</em> (Glycemia).</p> <p><strong>Transgene expression by SEAP measurement</strong></p> <p>Data for main <em>Figures 1, 2, 3, 4</em>.</p> <p>SEAP (human placental secreted alkaline phosphatase) levels were profiled in cell culture supernatants using a colorimetric assay. 100 &micro;L 2x SEAP assay buffer (20 mM homoarginine, 1 mM MgCl2, 21% diethanolamine, pH 9.8) was mixed with 80 &micro;L heat-inactivated (30 min at 65&deg;C) cell culture supernatant. After the addition of 20 &micro;L substrate solution (120 mM p-nitrophenyl phosphate; cat. no. AC128860100, Thermo Fisher Scientific), the absorbance time course was recorded for 45&thinsp;min at 405 nm and 37&deg;C using a Tecan Genios PRO plate reader (cat. no. P97084; Tecan Group AG, Maennedorf, Switzerland) and the SEAP levels were determined as follows: first, absorbance change over time (slope) was calculated. According to the Beer&ndash;Lambert&rsquo;s law, absorbance is proportional to the concentration of a colored compound and depends on the light path length (d) and extinction coefficient (&epsilon;) (&epsilon; for p-nitrophenyl (&epsilon;pNP)&thinsp;=&thinsp;18.600&thinsp;M&minus;1&thinsp;cm&minus;1). Enzymatic activity EA [U/L] was calculated from the equation: EA&thinsp;=&thinsp;slope&thinsp;&times;&thinsp;dilution factor&thinsp;&times;&thinsp;&epsilon;pNP&minus;1&thinsp;&times;&thinsp;d&minus;1&thinsp;</p> <p>Values in the file present determined SEAP levels.</p> <p><strong>Insulin by ELISA</strong></p> <p>Data for <em>Figures 5b, 6a, 6f</em>.</p> <p>Values in the file present Insulin level as determined by ELISA kit. The assay was performed according to manufacturer&rsquo;s instructions.</p> <p><strong>NanoLuc luciferase </strong></p> <p>Data for <em>Figures 5c, 6b, 6e</em>.</p> <p>NanoLuc&reg; luciferase was quantified in cell culture supernatants using the Nano-Glo&reg; Luciferase Assay System (cat. no. N1110; Promega, Duebendorf, Switzerland). In brief, 7.5 &micro;L of cell culture supernatant was added per well of a black 384-well plate and mixed with 7.5 &micro;L substrate-containing assay buffer. Total luminescence was quantified using a Tecan Genios PRO plate reader (Tecan Group AG).</p> <p>Values in the file present measured luminescence levels.</p> <p><strong>NanoLuc luciferase in vivo </strong></p> <p>Data for <em>Figure 7c.</em></p> <p>Aliquots of 15 &micro;L of whole-blood samples were diluted in 5 &mu;L of 50 mM EDTA and frozen at -20 &deg;C until NanoLuc&reg; quantification as described above.</p> <p>Values in the file present measured luminescence levels normalized to time point 0 (Normalization individually for each mouse).</p> <p><strong>Glycemia </strong></p> <p>Data for <em>Figures 7a, 7d</em>.</p> <p>Blood glucose level was determined using a glucometer (Contour&reg;Next, Bayer Healthcare, Leverkusen, Germany).</p> <p>Values in the file present measured glucose levels.</p> <p><strong>2. Figure 7b</strong>; Data for <em>Figure 7b</em>. File openable with Graphpad Prism.</p> <p>Blood glucose level was determined using a glucometer (Contour&reg;Next, Bayer Healthcare, Leverkusen, Germany).</p> <p>Values in the file present measured glucose levels.</p> <p><strong>3. Figure 6c and 6d</strong>; Excel file with the data for <em>Figures 6c, 6d</em>.</p> <p>NanoLuc&reg; luciferase was quantified in cell culture supernatants using the Nano-Glo&reg; Luciferase Assay System (cat. no. N1110; Promega, Duebendorf, Switzerland). In brief, 7.5 &micro;L of cell culture supernatant was added per well of a black 384-well plate and mixed with 7.5 &micro;L substrate-containing assay buffer. Total luminescence was quantified using a Tecan Genios PRO plate reader (Tecan Group AG).</p> <p>Values in the file present measured luminescence levels.</p>

opencc-by-4.0Jul 2021View details →
zenodo32/100

Hypoglycemia-induced electrocardiogram changes in a rodent model of type 1 diabetes

<p>Retrospective data was obtained from studies conducted by Reno et al. Adult male Sprague-Dawley rats (weight, 250&ndash;300 g; Charles River Laboratories, Malvern, PA) were housed individually in temperature- and light-controlled environments and fed ad libitum a standard chow diet and water. Rats underwent surgery for carotid artery and jugular vein cannulation as previously described. ECG leads were also placed subcutaneously during surgery. One wire was placed over the lower left rib cage and one was placed over the right supraclavicular fossa. A reference wire was placed over the back. Two days after cannulation, one set of rats received intraperitoneal injections of streptozotocin (65 mg/kg; Sigma, St. Louis, MO) to induce diabetes (n = 37). A second group of rats received sodium citrate buffer and acted as a control, non-diabetic group (n = 54). Blood glucose was measured from the tail vein with a glucometer (Ascensia Contour; Bayer HealthCare, Mishawaka, IN) to ensure diabetes. Rats were diabetic for two weeks prior to the hypoglycemic clamp. Overnight fasted, awake, unrestrained non-diabetic and diabetic rats underwent hyperinsulinemic (0.2 units &sdot; kg&minus;1 &sdot; min&minus;1; Humulin R), severe hypoglycemic (10&ndash;15 mg/dL) single step clamps with continuous ECGs for 3 hours, as previously described&nbsp; ECGs were recorded every millisecond (ms) using PowerLab 26T software (LabChart; ADInstruments, Colorado Springs, CO). Arterial blood was used to determine glucose levels during the clamp with a glucometer (Ascensia Contour BG monitors; Bayer Healthcare Mishawaka, IN) every 15-minutes.</p> <p>&nbsp;</p> <p>Reno CM, Daphna-Iken D, Chen YS, VanderWeele J, Jethi K, Fisher SJ. Severe hypoglycemia-induced lethal cardiac arrhythmias are mediated by sympathoadrenal activation. Diabetes. 2013;62(10):3570-81.</p> <p>&nbsp;</p> <p>Reno CM, VanderWeele J, Bayles J, Litvin M, Skinner A, Jordan A, et al. Severe Hypoglycemia-Induced Fatal Cardiac Arrhythmias Are Augmented by Diabetes and Attenuated by Recurrent Hypoglycemia. Diabetes. 2017;66(12):3091-7.</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p>

openattributionFeb 2023View details →
zenodo32/100

Association between a glucagon-like peptide 1 receptor genetic polymorphism and therapeutic response to sitagliptin in a sample of type 2 diabetic patients: an observational study

<p>Association between a glucagon-like peptide 1 receptor genetic polymorphism and therapeutic response to sitagliptin in a sample of type 2 diabetic patients: an observational study</p>

opencc-by-4.0Sep 2023View details →
ClinicalTrials.gov32/100

Feasibility Study of 2000 IU Per Day of Vitamin D for the Primary Prevention of Type 1 Diabetes

ClinicalTrials.gov study NCT00141986. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Acetazolamide in Persons With Type 1 Diabetes - Dose Finding

ClinicalTrials.gov study NCT05473364. IPD Sharing: NO. Countries: 1. Publications: 1.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov32/100

GIP and GLP-1 in Type 1 Diabetes

ClinicalTrials.gov study NCT01739283. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

The Effect of Motivational Interviewing in Children With Type 1 Diabetes

ClinicalTrials.gov study NCT06424574. IPD Sharing: NO. Countries: 1. Publications: 3.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov32/100

Markers of Bone Status in Diabetes Mellitus (Type 1 and Type 2)

ClinicalTrials.gov study NCT01870557. IPD Sharing: Not stated. Countries: 1. Publications: 3.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Activation Innate Immune System in Type 1 Diabetes

ClinicalTrials.gov study NCT03441919. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Monotherapy With Rapamycin in Long-standing Type 1 Diabetes

ClinicalTrials.gov study NCT02803892. IPD Sharing: YES. Countries: 1. Publications: 1.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov32/100

Food Literacy and Type 1 Diabetes

ClinicalTrials.gov study NCT03588234. IPD Sharing: NO. Countries: 1. Publications: 4.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov32/100

Closing the Loop in Young Children With Type 1 Diabetes

ClinicalTrials.gov study NCT01557634. IPD Sharing: Not stated. Countries: 1. Publications: 3.

restrictedIPD-UNDECIDEDFeb 2026View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record